Retatrutide (10mg)

What is Retatrutide (10mg)?

Retatrutide is a synthetic investigational peptide agonist that acts at three incretin and metabolic receptors — GLP-1, GIP and the glucagon receptor — and is described in the research literature as a "triple agonist".

It is studied in metabolic-research contexts for its combined receptor activity and effects on energy-balance pathways in models. This is an investigational research compound, not an approved medicine; it is supplied strictly for research use only and is not for human or veterinary use.

Documentation

Documentation status for Retatrutide (10mg) is shown on its product record.

Frequently asked questions

What is Retatrutide (10mg)?

Retatrutide (10mg) is a research compound in the Repair and metabolic peptides category supplied by East Coast Labs strictly for laboratory research use only. It is not for human or veterinary use.

Is Retatrutide (10mg) for human use?

No. Retatrutide (10mg) is supplied for laboratory research use only and is not intended for human or veterinary use, consumption, or therapeutic application.

Selected research literature

Peer-reviewed references retrieved from PubMed, provided for research context. These are links to published studies and do not constitute a health claim about this product.

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023. PubMed 37366315 DOI
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet 2023. PubMed 37385280 DOI

Citation data via PubMed (U.S. National Library of Medicine).